Hi {{ first name | there}},
Most people think metabolic health is mainly a blood sugar story: glucose, HbA1c, insulin, weight, waist, maybe triglycerides. Those numbers matter, and they are often the first place to look. But they can also make the dashboard feel more complete than it really is.
A new study points to a quieter layer of risk: the liver’s stiffness.
That matters since the liver is not just a filter. It is a metabolic command center that helps manage glucose, lipids, inflammation, clotting signals, energy storage, detoxification, and hormone handling. When metabolic stress keeps hitting the liver, fat can build up. In some people, that becomes inflammation. In some, it becomes fibrosis – scar-like tissue that makes the liver stiffer.
And that is the part many people miss. Blood sugar may tell you one part of the metabolic story, while liver stiffness may tell you whether the story has already started leaving a mark.
Last week’s poll pointed to the same bigger theme: the body often keeps a record before we do. 30.8% said travel is when antibiotics usually enter the picture, 30.2% said they try to avoid antibiotics unless clearly needed, and 23.7% said they have had repeated courses and should probably look at the pattern. Another 7.8% had antibiotics in the last year and had not thought much about recovery, while 7.5% do not clearly remember their antibiotic history.
This week, the record is not in your antibiotic history. It may be in the liver layer of metabolic risk – the one glucose alone can miss.
Evidence-first health, delivered – and built.
And if this issue helps, forward it to one person who still thinks metabolic health is only about blood sugar. Subscribe here.
Want the full Deep Dive? Upgrade to HEALTH HACK Pro and the Pro sections unlock on the web version right away.
-LONGEVITY PLAYBOOK-
The Liver Signal Blood Sugar Can Miss
A new JAMA Network Open cohort study adds a sharper layer to the metabolic-health conversation: the liver may be carrying risk that glucose numbers do not fully reveal. The researchers looked at 4,102 adults with liver stiffness data from vibration-controlled transient elastography, often known through FibroScan-style testing, and asked whether liver stiffness added mortality-risk information in people with diabetes.
The answer was hard to ignore. In the study, diabetes alone mattered. Metabolic liver disease mattered. But the combination of diabetes and advanced liver fibrosis carried a much stronger signal. People with both diabetes and advanced liver fibrosis had a higher adjusted risk of all-cause mortality than people without that combination. Among people with diabetes, liver stiffness measurement remained associated with mortality even after adjustment for age, sex, BMI, and HbA1c. FIB-4, the common blood-based fibrosis score, did not remain associated in the same way in that diabetes subgroup.
That is the gap this issue is about. HbA1c tells you how much glucose has been attaching to hemoglobin over roughly the past few months. It is useful, but it does not tell you how much liver fat has accumulated, whether inflammation is brewing, or whether fibrosis has started to form. Blood sugar tells you about fuel traffic. Liver stiffness may tell you whether the roads are being damaged.
This is especially relevant for people with type 2 diabetes, prediabetes, central fat gain, high triglycerides, hypertension, sleep apnea, or a history of elevated liver enzymes. These are not separate health stories. They often travel together under the broader umbrella of metabolic dysfunction-associated steatotic liver disease, or MASLD.
Current diabetes guidance already recognizes the issue. The usual pathway starts with FIB-4, a simple score built from age, AST, ALT, and platelets. If FIB-4 is elevated, further evaluation may include liver stiffness measurement or another non-invasive fibrosis test. The new study adds a sharper message: in people with diabetes, liver stiffness may carry risk information that routine scoring can miss.
This is the useful part.
Do not turn this into panic. Turn it into a better question.
If your metabolic health story is mostly built around glucose, ask: What does my liver layer show? That starts with routine labs: ALT, AST, GGT, platelets, triglycerides, fasting glucose, HbA1c, and sometimes ferritin. It may include a FIB-4 calculation. For higher-risk people, it may justify a clinician-guided conversation about liver stiffness testing.
The point is not to chase every scan. The point is to stop assuming that “blood sugar looks fine” means the liver is fine.
In metabolic health, the visible number is not always the whole signal.
Unlock the deeper read: what liver stiffness actually means, where FIB-4 helps, where it can miss risk, and the decision rule that keeps this from becoming another test-chasing spiral.
THE MOVE
The Liver-Risk Layer
This week, pull up your most recent blood panel and look beyond glucose. Start with ALT, AST, GGT, platelets, and HbA1c, then add the context that changes the meaning of those numbers: triglycerides, waist trend, blood pressure, alcohol pattern, sleep apnea risk, and whether you have diabetes or prediabetes.
The goal is not to diagnose yourself from a spreadsheet. The goal is to see whether your metabolic dashboard has a missing liver layer.
If you have type 2 diabetes, prediabetes, central fat gain, high triglycerides, persistently elevated liver enzymes, or sleep apnea risk, prepare one clinician question: “Should we calculate FIB-4, and would liver stiffness testing make sense in my case?”
Scoreboard:
ALT/AST checked: yes/no
GGT checked: yes/no
Platelets checked: yes/no
FIB-4 question prepared: yes/no
Liver-risk context reviewed: yes/no
Reply with: LIVER LAYER: 0-5
Unlock the full protocol: the 7-day and 14-day liver-risk check, what to track, what can distort the numbers, when to ask about FibroScan-style testing, and the stop rules that keep this useful instead of messy.
-SPONSORED-
The free printable plan seniors can't stop talking about.
BIOMARKER OF THE WEEK – GGT
GGT stands for gamma-glutamyl transferase. It is often filed away as a “liver enzyme,” or even more narrowly as an alcohol-related marker, but that is too small a box for it.
GGT can rise when the liver and bile system are under strain. It is also linked with broader cardiometabolic risk patterns, including metabolic syndrome, fatty liver, cardiovascular disease, and mortality risk in observational research. That does not make it a diagnosis. It makes it a useful context marker – especially when the issue is liver stress hiding behind a glucose-focused dashboard.
The key is not to read GGT alone. A slightly elevated GGT means something different when it sits next to high triglycerides, central fat gain, prediabetes, sleep apnea risk, higher ALT/AST, or frequent alcohol exposure. In MASLD guidance, case-finding for liver fibrosis is especially relevant in people with cardiometabolic risk factors, abnormal liver enzymes, type 2 diabetes, or obesity with additional metabolic risk.
Better usually means lower and stable within your lab’s reference range, but trend matters. A GGT that quietly climbs over repeated blood panels can be more interesting than one isolated result. What can distort it: alcohol, some medications, bile-duct issues, recent illness, intense training, rapid weight change, and lab variation.
The practical rule:
Do not treat GGT as “the answer.” Treat it as a signal that deserves context.
Unlock the measurement upgrade: how to track GGT without fooling yourself, what noise to ignore, which patterns matter, and when a clinician conversation becomes more useful than another spreadsheet.
-MYTH OF THE WEEK-
“If Liver Enzymes Are Normal, the Liver Is Fine.”
This is one of the most common metabolic-health blind spots.
ALT and AST are useful liver enzymes, but they are not a full fibrosis screen. They can look normal even when metabolic risk is building in the background, especially in people with type 2 diabetes, prediabetes, central fat gain, high triglycerides, or sleep apnea risk.
That is why clinical pathways often start with routine labs, then add a fibrosis-risk layer such as FIB-4, and, when appropriate, a second-line test such as liver stiffness measurement or ELF testing. The goal is not to scare people into extra testing. The goal is to avoid treating normal liver enzymes as the final word when the broader risk pattern says otherwise.
The safer belief is this:
Normal liver enzymes reduce concern. They do not erase context.
If your glucose, triglycerides, waist trend, blood pressure, sleep, alcohol pattern, and liver markers are all moving in the right direction, that is reassuring. If several of those signals are moving the wrong way, “normal ALT” should not be used as a permission slip to ignore the liver layer.
In metabolic health, the pattern matters more than one comfortable number.
THE TOOL
FIBROSCAN-STYLE LIVER STIFFNESS TESTING
FibroScan is the best-known brand name for vibration-controlled transient elastography, or VCTE. It is a non-invasive test that estimates how stiff the liver is. Higher stiffness can point toward fibrosis risk, although the result still needs clinical interpretation and should be read alongside labs, metabolic risk, alcohol pattern, medications, and history.
This fits the issue since the new JAMA Network Open study used liver stiffness measurement and found that, among people with diabetes, it remained associated with all-cause mortality even after adjustment for age, sex, BMI, and HbA1c. In that same diabetes subgroup, FIB-4 did not remain associated in the same way.
That does not make FibroScan-style testing a wellness gadget. It makes it a second-layer tool. The usual path starts with risk context and routine labs, then often a blood-based score like FIB-4, followed by liver stiffness testing when the risk picture calls for a closer look. Current MASLD guidance supports this kind of stepwise approach, especially in people with cardiometabolic risk factors, abnormal liver enzymes, type 2 diabetes, or obesity with additional metabolic risk.
The practical rule is simple: use liver stiffness testing to clarify risk, not to replace behavior. If glucose, triglycerides, waist trend, blood pressure, sleep apnea risk, alcohol pattern, and liver markers are all pointing in the same direction, the liver layer deserves attention. If you are low-risk with stable normal labs and no relevant history, this is usually not the first tool to chase.
Unlock the tool notes: when FibroScan-style testing makes sense, what to pair it with, what can distort the result, what can backfire, and who should use clinician-guided interpretation rather than DIY scoring.
-IN THE PRESS-
What we're reading
The Plant-Based Label Is Not a Quality-Control System
A new survey of 212 UK plant-based meat alternatives and beverages found at least one mycotoxin in every tested product, although levels were below EU guideline limits. The signal is not panic. It is that “plant-based” does not automatically mean clean, minimally processed, or risk-free.
Phys.org
HEALTH HACK take: Health-positioned foods still need the same question as every other food: what is it made from, how processed is it, and what does repeated exposure look like?
The Fat Depot Your Brain May Care About Most
A new study linked higher visceral fat – the fat stored around organs – with faster brain-aging markers, while subcutaneous fat did not show the same relationship. Glucose and insulin appeared to be part of the bridge between abdominal fat and brain structure.
ScienceAlert
HEALTH HACK take: The scale can miss the risk. The more useful question is not only “How much fat?” but where is it stored, and what is it doing to glucose and insulin signaling?
Your Job Steps May Not Count Like Your Workout
A pooled analysis of 44 studies and 145,465 people found that leisure-time activity was linked with younger readings on some epigenetic clocks, while occupational activity showed no such relationship. The difference may come down to intensity, recovery, autonomy, and the stress context around the movement.
Earth.com
HEALTH HACK take: Movement is not just movement. A walk you choose may send a different biological signal than movement you endure.
Peppermint Oil and Blood Pressure: Interesting, Not Settled
A small clinical trial found that 100 microliters of peppermint oil twice daily for 20 days lowered systolic blood pressure by an average of 8.5 mmHg in people with mildly high readings. That is interesting, but still early, narrow, and not a replacement for blood-pressure fundamentals.
Medical Xpress
HEALTH HACK take: Treat this as a signal to watch, not a shortcut. The boring levers still come first: home blood-pressure tracking, sleep, sodium, alcohol, weight trend, training, and medication review when needed.
The Hearing Aid That Listens to Your Brain
Columbia researchers showed early human evidence that a real-time brain-controlled hearing system can identify which speaker someone is focusing on and amplify that voice while reducing competing speech. The work used implanted electrodes in epilepsy patients, so this is not consumer-ready – but it is a fascinating glimpse of where assistive hearing may go.
Neuroscience News
HEALTH HACK take: The future of hearing support may not be louder sound. It may be better signal selection – helping the brain hear the conversation it is already trying to follow.
-SPONSORED-
Rugiet Ready™ is a 3-in-1 ED treatment that targets your brain and body. Dissolves under your tongue. Works in as little as 15 minutes. No pill. No guesswork. Try Ready™ now.
-PEPTIDE WATCH-
FGF21 ANALOGS – THE LIVER SIGNAL MOVING INTO MEDICINE
FGF21 is a hormone-like metabolic signal involved in energy balance, lipid handling, insulin sensitivity, and liver-fat biology. Drug developers are trying to turn that signal into therapies for MASH, the more inflammatory and fibrotic form of metabolic liver disease.
This is not wellness-stack territory.
This is clinical-drug territory.
FGF21 analogs such as pegozafermin and efruxifermin have shown promising human trial signals in MASH and fibrosis-related endpoints. In a phase 2b trial, pegozafermin improved fibrosis outcomes over 24 weeks in patients with biopsy-confirmed NASH/MASH and stage F2-F3 fibrosis. Efruxifermin has also shown fibrosis-related signals in longer phase 2b MASH programs.
Grey-market reality check
FGF21 analogs are starting to attract attention in the high-end biohacking world, partly since the field now looks like the next metabolic frontier after GLP-1s. But these compounds are not simple “mix-and-inject” peptides. Efruxifermin, for example, is described by Akero as an Fc-FGF21 fusion protein being developed for MASH, while pegozafermin is an investigational FGF21 analog being advanced for liver and cardiometabolic disease. These are clinical biologic-style drug candidates, not casual wellness inputs.
That distinction matters. With grey-market versions, the risks are not only “is this real?” The risks include incorrect identity, poor handling, failed cold-chain storage, improper folding, immune reactions, and no clinical monitoring. The serious evidence for FGF21 analogs comes from controlled trials in defined disease populations, including phase 2b work in biopsy-confirmed NASH/MASH and fibrosis – not from self-experimentation forums.
The smart move is not to chase the compound. It is to understand why medicine is moving toward the liver-fibrosis layer in the first place.
What it is
FGF21 stands for fibroblast growth factor 21. Native FGF21 is short-lived, so investigational drug candidates are engineered to last longer and produce a more durable therapeutic signal.
The appeal is obvious: instead of only pushing weight loss or glucose, these drugs aim at the metabolic-liver interface – liver fat, lipid handling, inflammation, insulin sensitivity, and fibrosis biology.
That makes them scientifically exciting.
It does not make them consumer tools.
The evidence: claims vs reality
The liver-fibrosis drug landscape is changing fast. The FDA approved resmetirom in 2024 as the first treatment for adults with noncirrhotic NASH/MASH with moderate-to-advanced fibrosis, used with diet and exercise. In 2025, the FDA also approved Wegovy for adults with noncirrhotic MASH with moderate-to-advanced liver scarring, also alongside diet and increased physical activity.
That matters for this issue.
For years, fatty liver was often treated like a vague lifestyle warning. Now, fibrosis risk is becoming a serious therapeutic category. Pharmaceutical pipelines are not chasing “liver detox.” They are chasing fibrosis, inflammation, and metabolic injury.
FGF21 analogs sit inside that bigger shift. They are a research signal that the liver layer is not secondary. It may be central.
Decision rule
Do not make FGF21 analogs the intervention.
Make them the clue.
If medicine is moving toward fibrosis-focused metabolic-liver therapy, the consumer move is not to chase investigational compounds. It is to ask the upstream question:
Am I tracking the liver layer of metabolic risk at all?
That starts with risk context, routine labs, FIB-4 when appropriate, and clinician-guided liver stiffness testing when the pattern calls for it.
Hard disclaimer
This section is educational only. FGF21 analogs are not a self-experiment. Do not self-source peptides, “research compounds,” or investigational drugs. Do not use this section to seek a protocol. If you have known or suspected liver disease, discuss testing and treatment options with a qualified clinician.
Unlock the peptide dossier: evidence grade, what the human trials actually show, why grey-market FGF21 analogs are riskier than ordinary peptide hype, the biohacker risk filter, clinician discussion questions, and the safer upstream move to run first.
QUICK POLL
What is the liver-risk blind spot you are most likely to miss?
QUOTE TO REMEMBER
💡 Blood sugar tells you about fuel traffic. Liver stiffness may tell you whether the roads are being damaged.
Closing Note
The best health systems are not built on hype.
They are built on seeing the layer most people ignore.
This week, that layer is the liver: not as a detox cliché, but as a metabolic signal that may show strain before you feel anything.
If you run The Liver-Risk Layer, reply with your scoreboard:
LIVER LAYER: 0-5
And if this issue helped, forward it to one person who still thinks metabolic health is only about blood sugar.
Want the Pro version? Unlock the full protocol, measurement upgrade, tool notes, stop rules, and this week’s peptide dossier: Upgrade
Until next time,
Live longer. Upgrade wisely.
Rolf & the HEALTH HACK team
PS: If someone sent you this, you can subscribe here: HEALTH HACK Newsletter
Disclaimer
Educational only. Not medical advice. Do not delay care. Consult your clinician for personal decisions – especially around symptoms, tests, supplements, medications, or peptides. Do not self-source peptides.